FDA Gives Positive Pre-IND Feedback for Novel mRNA Therapy Targeting Familial Hypercholesterolemia
Key Insights
Repair Biotechnologies (search) receives FDA support for their proposed Phase 1b clinical trial of REP-0003, an mRNA therapy designed to reduce atherosclerotic plaque in HoFH patients.
Preclinical studies demonstrated significant plaque regression and improved exercise capacity in LDLR-knockout mice, showing promise for treating this rare genetic condition.
The company's proprietary Cholesterol Degrading Platform technology aims to address the unmet medical need in HoFH patients who face early mortality from heart attacks and strokes.
Repair Biotechnologies (search) has achieved a significant milestone in advancing its innovative mRNA therapy for treating homozygous familial hypercholesterolemia (search) (HoFH), following positive feedback from the FDA during a Pre-IND meeting. The company's lead candidate, REP-0003, targets the critical unmet need in patients suffering from this rare genetic condition characterized by accelerated atherosclerosis (search).
Clinical Development Strategy
The FDA reviewers expressed alignment with Repair Biotechnologies (search)' proposed clinical development program, specifically endorsing their clinical trial design, IND-enabling studies, and drug manufacturing processes. A key focus of the Pre-IND meeting was establishing appropriate clinical endpoints to demonstrate improved function in HoFH patients following REP-0003 treatment.
"HoFH remains a condition of high unmet need, reduced quality of life, and early mortality from plaque rupture leading to heart attack and stroke," stated Reason, CEO and Co-Founder of Repair Biotechnologies (search). "We hope to be able to make a real difference for this patient population."
Promising Preclinical Results
The therapeutic potential of REP-0003 has been demonstrated through preclinical studies using LDLR-knockout mice, which mirror the human condition through loss-of-function mutations in the low-density lipoprotein receptor (search) gene. The studies showed significant and reliable regression of atherosclerotic plaque accompanied by improved exercise capacity - a crucial metric, as HoFH patients typically experience reduced exercise tolerance among other complications of accelerated atherosclerosis (search).
Innovative Technology Platform
REP-0003 was developed using Repair Biotechnologies (search)' proprietary Cholesterol Degrading Platform (CDP), representing a novel approach to addressing toxic excess intracellular cholesterol in tissues. This platform technology provides a method to safely break down and eliminate this previously undruggable target, with potential applications extending beyond HoFH to conditions related to aging and obesity.
The planned Phase 1b study will focus on demonstrating the therapy's ability to reduce atherosclerotic plaque volume, with exercise capacity serving as a key functional endpoint. This approach aligns with the FDA's emphasis on meaningful clinical outcomes that directly impact patient quality of life.